Welcome to our dedicated page for DALRADA FINCL news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on DALRADA FINCL stock.
Dalrada Financial Corporation, through its subsidiaries, provides various products and services in the manufacturing, engineering, and healthcare sectors worldwide. The company offers low-carbon heating and cooling systems, visual inspection kits for detecting cervical cancer, and software solutions in test engineering, accessibility engineering, and more. Additionally, it provides cleaning solutions with electrostatic machines for various facilities. Formerly known as Imaging Technologies Corporation, Dalrada Financial Corporation was incorporated in 1982 and is headquartered in Escondido, California.
The company, under the leadership of CEO Brian Bonar, focuses on driving innovation in the Clean Energy and Health Care sectors. Its segments include Dalrada Climate Technology and Genefic Specialty Pharmacy, offering advanced heat pump technology and end-to-end prescription services, respectively. With a commitment to sustainability and cutting-edge solutions, Dalrada Financial Corporation aims to deliver value to its shareholders.
Dalrada Corporation (DFCO) has established a Clean Energy Advisory Board, featuring significant leaders in climate and business, including former U.S. Secretary of the Interior, Ryan Zinke. The board aims to forge strategic alliances for sustainable development and responsible environmental policies. Zinke emphasizes the importance of energy-efficient technologies that reduce carbon footprints. Dalrada's innovative low-carbon heating and cooling technology utilizes supercritical CO2, aiming to enhance energy efficiency while minimizing emissions.
Dalrada Corporation (OTCQB: DFCO) announced a remarkable 189% revenue surge to $3,406,684 for fiscal year 2021, compared to $1,178,154 in 2020. The growth was fueled by its subsidiaries: Dalrada Health, Dalrada Technology, and Dalrada Precision. Highlights included key acquisitions, product launches, and client expansions. Operating expenses rose to $9,504,869 from $3,241,335 due to increased activity. Despite this, Dalrada reported a net income of $1,221, rebounding from a net loss of $2,477,557 the previous year. The company’s board continues to attract industry leaders to drive innovation.
Dalrada Corporation (OTCQB: DFCO) has announced its community outreach initiative providing free COVID-19 point-of-care tests at events, including the Boise Pride Festival. Pala Diagnostics, a joint venture with Vivera Pharmaceuticals, administered nearly 3,000 rapid antigen and PCR tests, ensuring compliance with health protocols. The collaboration aims to restore safe public gatherings, reflecting the company's commitment to innovative health solutions. As part of its strategy, Dalrada focuses on disruptive solutions across its business divisions to address global challenges.
Dalrada Corporation (OTCQB: DFCO) has announced that its Q1 2022 gross revenues are on track to exceed the combined gross revenues of the last eight quarters, pending review. CEO Brian Bonar emphasized Dalrada's commitment to providing innovative solutions in healthcare, clean energy, and technology. The company aims to meet current healthcare industry needs with affordable and accessible products. Established in 1982, Dalrada focuses on engineering, life sciences, and technology, with subsidiaries dedicated to impactful innovations.
Dalrada Corporation (OTCQB: DFCO) has announced the opening of two new subsidiaries under Dalrada Health. Pala Diagnostics is a national laboratory for COVID-19 testing, providing rapid antigen and PCR testing, while Sòlas Rejuvenation + Wellness offers advanced wellness programs. CEO Brian Bonar emphasized the importance of accurate health testing amidst the ongoing health crisis, highlighting Pala’s CLIA-certified lab's rapid results and mobile services. Dalrada Health aims to improve global health accessibility and affordability.
Dalrada Corporation (OTCQB: DFCO) has announced a joint venture between its subsidiary Dalrada Health and Vivera Pharmaceutical, Inc., creating Pala Diagnostics, LLC. This initiative aims to enhance COVID-19 testing capabilities, providing rapid results and life science testing services. Pala Diagnostics will initially offer EUA-approved rapid antigen tests and lab-based PCR testing. The collaboration seeks to support businesses and educational institutions as they reopen safely. The venture taps into Vivera's extensive healthcare network and expertise in pharmaceuticals and diagnostics.
Dalrada Corporation (OTCQB: DFCO) has appointed The Honorable Bijan R. Kian, Jose Arrieta, and Kyle McCollum to its Board of Directors. CEO Brian Bonar expressed enthusiasm for these appointments, highlighting their extensive experience in global trade, technology, and finance, which will enhance the company's initiatives in engineering, health, and clean energy. The new board members aim to accelerate Dalrada’s growth and innovation across its diverse sectors. With a commitment to disruptive solutions, Dalrada continues to strive for accessibility and positive change globally.
Dalrada Corporation (DFCO) announces its subsidiary, Dalrada Precision, has entered the eco-friendly degreaser market with Ignite Industrial Technologies’ products. These biodegradable cleaners offer a safer and more effective solution for manufacturing efficiency. The global cleaner and degreaser market is expected to grow, with the aftermarket projected to reach USD 42.63 billion by 2026. Ignite products are designed to be environmentally friendly, non-toxic, and effective for various industrial applications. This innovation positions Dalrada to capitalize on the increasing demand for sustainable cleaning solutions.
Dalrada Corporation (DFCO) announces a strategic partnership between its IT engineering subsidiary, Prakat Solutions, and ValueQwest Pte. Ltd. to enhance the digital transformation of global supply chains. A report indicates a substantial growth in the digital transformation market, predicting logistics spending to reach $75.5 billion by 2026, growing at a CAGR of 8.8%. This collaboration aims to develop scalable solutions and a talent pool of specialists in supply chain technologies, benefiting clients across 17 countries, including major firms like Microsoft and Oracle.
Dalrada Corporation (OTCQB: DFCO) has announced the appointment of Dr. David Bacon to its Board of Directors. Dr. Bacon brings over 22 years of active Navy experience and has been instrumental in evaluating funding proposals during the SARS-CoV-2 pandemic. His extensive background includes key roles in various defense-related health programs and significant scientific contributions, including 35 peer-reviewed publications. CEO Brian Bonar stated that Dr. Bacon’s expertise will enhance Dalrada Health's product development. The Board now comprises leaders from various sectors, focusing on innovative health and sustainability solutions.
FAQ
What is the current stock price of DALRADA FINCL (DFCO)?
What is the market cap of DALRADA FINCL (DFCO)?
What products and services does Dalrada Financial Corporation offer?
When was Dalrada Financial Corporation incorporated?
Where is Dalrada Financial Corporation headquartered?
Who is the CEO of Dalrada Financial Corporation?
What are the core segments of Dalrada Financial Corporation?
What is the focus of Dalrada Financial Corporation?
What is the mission of Dalrada Financial Corporation?
